ACS Fall 2025的新分子結(jié)構(gòu)及其在多個(gè)疾病研究領(lǐng)域的應(yīng)用

化學(xué)界"燃爆現(xiàn)場(chǎng)"——ACS Fall 2025 (美國(guó)化學(xué)會(huì)秋季年會(huì)) 在美國(guó)華盛頓舉行！速來(lái)瀏覽科研新鮮事兒~

在 Medicinal Chemistry 的 First-Time Disclosures 專(zhuān)場(chǎng)里，13 位科研先鋒首次公開(kāi)了「潛力爆棚」的新分子結(jié)構(gòu)，覆蓋寄生蟲(chóng)病、心臟病、炎癥、帕金森影像劑、腫瘤等諸多領(lǐng)域。

不只是小分子，還有 molecular glue、stapled peptide 乃至放射示蹤探針，多種創(chuàng)新藥物形態(tài)齊登臺(tái)，實(shí)在太燃了！

Section.01
精選亮點(diǎn)搶先看

 
Section.02
小結(jié)

ACS Fall 2025 的新分子披露，不僅展示了藥物化學(xué)前沿的多樣性與創(chuàng)造力，也為臨床轉(zhuǎn)化打開(kāi)了新的大門(mén)。未來(lái)幾年，這些“初登場(chǎng)”的分子，或許會(huì)成為改變疾病治療格局的關(guān)鍵力量。

[1] H Rachel Lagiakos, et al. Discovery of IID432: A highly efficacious and safe cyanotriazole inhibitor of Trypanosoma cruzi topoisomerase II for short-duration curative treatment of Chagas disease. ACS. 2025 Aug 20.
[2] Thomas Cummins, et al. Discovery of BMS-986470, a first-in-class molecular glue dual degrader of zinc finger and BTB domain containing 7A (ZBTB7A) and widely interspaced zinc finger protein (WIZ) for the treatment of treatment of Sickle Cell Disease. ACS. 2025 Aug 20.
[3] Leena Patel, et al. Discovery of GS-1427: A potent and selective, oral α4β7 inhibitor for the treatment of inflammatory bowel disease. ACS. 2025 Aug 20.
[4] David Ebner, et al. Development of colon-targeted pan-SIK inhibitor PF-07899895 for the treatment of IBD. ACS. 2025 Aug 20.
[5] Karolina Nilsson, et al. AZD0233: An oral CX3CR1 antagonist in development for the treatment of cardiovascular disease. ACS. 2025 Aug 20.
[6] Michael Green, et al. Discovery of clinical candidate PF-07293893: A novel and selective AMPK gamma 3 activator for the treatment of heart failure. ACS. 2025 Aug 20.
[7] Helen Mitchell, et al. Discovery of [11C]MK-7337, a novel high-affinity alpha-synuclein PET ligand for imaging in idiopathic Parkinson’s disease patients. ACS. 2025 Aug 20.
[8] Jennifer Riggs, et al. Discovery of a first-in-class molecular glue degrader of WEE1 kinase, BMS-986463, for the treatment of advanced malignant solid tumors. ACS. 2025 Aug 20.
[9] Robert Hudkins, et al. TYRA-200: Next generation inhibitor designed to potently target FGFR2 alterations and resistance mutations. ACS. 2025 Aug 20.
[10] Meredeth McGowan, et al. Discovery of MOMA-341, a chemically distinct, potent and selective covalent inhibitor of Werner Syndrome Helicase (WRN). ACS. 2025 Aug 20.
[11] Krista Goodman, et al. Discovery of LRK-4189, a first-in-class degrader of the lipid kinase PIP4K2C for the treatment of Microsatellite Stable (MSS) Colorectal Carcinoma. ACS. 2025 Aug 20.
[12] Brian White, et al. Discovery of FOG-001, a clinical stage Helicon inhibitor of the beta-catenin/TCF4 interaction. ACS. 2025 Aug 20.
[13] Chunhui Huang, et al. ETN029: Discovery and development of a DLL3-targeting radioligand therapy for the treatment of SCLC and beyond. ACS. 2025 Aug 20.